Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study
Authors:
- for the CASE-J Study GroupFGfor the CASE-J Study Group
- 24 April 2009
- journal article
- research article
- Published by Springer Nature in Hypertension Research
- Vol. 32 (6) , 505-512
Abstract
We examined the effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease (CKD) using the data from the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. CKD was defined as proteinuria and/or decreased GFR (2) at enrollment. Among 2720 subjects with CKD, there were 1376 and 1344 patients in the candesartan and the amlodipine group, respectively. During a 3.2-year follow-up, cardiovascular event rate did not differ in the two groups (7.2% for candesartan and 7.6% for amlodipine). In the subgroup analysis based on the CKD stage, there were no significant differences in the incidence rates of cardiovascular events between the two groups in stages 1+2 and 3 CKD. In stage 4 CKD, however, candesartan reduced the incidence of cardiovascular events (55% risk reduction), particularly of renal events (81% risk reduction), compared with amlodipine. Furthermore, composite cardiovascular events were increased as the CKD stage progressed, and this effect was exaggerated in the presence of proteinuria. Finally, the new onset of diabetes was less in the candesartan-based regimen in stage 3 CKD. In conclusion, candesartan protected hypertensive patients with CKD more potently against renal events, particularly in moderately–to–severely impaired CKD. Furthermore, candesartan prevented a new onset of diabetes in CKD, which would be favorable for the long-term management of CKD.Keywords
This publication has 33 references indexed in Scilit:
- Effects of Candesartan Compared With Amlodipine in Hypertensive Patients With High Cardiovascular RisksHypertension, 2008
- Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficientClinical and Experimental Nephrology, 2007
- Insulin Resistance, Inflammatory Biomarkers, and Adipokines in Patients with Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2006
- Vascular and metabolic effects of candesartan: insights from therapeutic interventionsJournal Of Hypertension, 2006
- Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004)Hypertension Research, 2006
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension, 2003
- Proteinuria and the risk of developing end-stage renal diseaseKidney International, 2003
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- Guidelines for the Management of Hypertension for General Practitioners.Hypertension Research, 2001